Compare SPRU & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPRU | LUNG |
|---|---|---|
| Founded | 2008 | 1995 |
| Country | United States | United States |
| Employees | 4 | N/A |
| Industry | Auto Parts:O.E.M. | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.2M | 57.9M |
| IPO Year | 2019 | 2020 |
| Metric | SPRU | LUNG |
|---|---|---|
| Price | $2.91 | $1.66 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 46.5K | ★ 501.7K |
| Earning Date | 05-13-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.30 | 7.64 |
| EPS | ★ N/A | N/A |
| Revenue | $23,194,000.00 | ★ $90,497,000.00 |
| Revenue This Year | N/A | $2.48 |
| Revenue Next Year | N/A | $18.46 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 48.68 | 8.01 |
| 52 Week Low | $1.13 | $1.13 |
| 52 Week High | $6.75 | $3.88 |
| Indicator | SPRU | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 37.35 | 68.55 |
| Support Level | $2.56 | $1.51 |
| Resistance Level | $3.32 | $1.93 |
| Average True Range (ATR) | 0.23 | 0.10 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 27.20 | 89.90 |
Spruce Power Holding Corp is an owner and operator of distributed solar energy assets across the United States (the U.S.), offering subscription-based services to home solar assets and customer contracts, making renewable energy more accessible to everyone. The Company's customers are homeowners and the Company's core solar service offerings generate revenues through, the sale of electricity generated by its home solar energy systems to homeowners, third-party contracts to sell solar renewable energy credits (SRECs) generated by the solar energy systems for fixed prices and the servicing of those agreements for other institutional owners of home solar energy systems.
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.